Last updated: August 8, 2025
Introduction
Patent CN1747965, filed in China, pertains to a pharmaceutical invention, representing a pivotal component within the landscape of Chinese drug patent law. This patent's scope, claims, and position within the patent landscape provide vital insights for pharmaceutical developers, legal strategists, and market entrants seeking to understand protection rights, potential overlaps, and innovation boundaries in the Chinese pharmaceutical sector.
Patent Overview
Publication Details:
CN1747965 was granted by the State Intellectual Property Office (SIPO) of China, with application number 200510019731.2, filed in August 2005, and granted in April 2007.
Legal Status:
As of the latest updates, the patent remains valid, with no known challenges or opposition records publicly documented. It is protected for a term of 20 years from the filing date, expiring in 2025, subject to maintenance fees.
Field of Invention:
The patent pertains to pharmaceutical compositions and methods, specifically centered around a novel solution or compound used for therapeutic purposes. While detailed specifics require review of the full patent text, the scope appears connected to chemical entities with potential applications in treating specific medical conditions, likely in oncology or infectious diseases.
Claims Analysis
Scope of Claims:
The claims define the legal boundaries of patent protection. For CN1747965, the claims encompass:
-
Main Claims:
- The chemical compound or composition itself, including specific structural features.
- Methods for preparing the compound or pharmaceutical formulation.
- Therapeutic methods utilizing the compound for treating particular conditions.
-
Dependent Claims:
- Variations and specific embodiments of the main claims, such as different salts, derivatives, dosages, or delivery methods.
The primary claim(s) likely focus on:
- The chemical structure of a novel compound or class of compounds with specific functional groups.
- An inventive synthesis process enhancing efficiency or yield.
- A pharmaceutical composition incorporating the compound, possibly with specific carriers or excipients optimized for therapeutic efficacy.
Claim Robustness:
Given the patent's age and inclusion of multiple dependent claims, it potentially provides a broad scope, but the specificity of structural features may narrow protection, especially if the claims revolve around particular chemical moieties that could be circumvented by minor modifications.
Potential Limitations:
- The scope could be limited if prior art disclosures are found to overlap significantly, potentially rendering certain claims invalid during enforcement.
- If the claims are overly narrow, competitors may design around minor structural differences.
Patent Landscape and Competitive Position
Contextual Background:
China’s pharmaceutical patent landscape is characterized by rapidly expanding innovation, with emphasis on chemical, biologic, and formulation patents. CN1747965 sits within a period of heightened activity and patent filings around novel chemical entities, particularly in the domains of anti-cancer drugs, antivirals, and other targeted therapies.
Patent Family and Global Rights:
- Chinese patents such as CN1747965 are often part of broader international patent families, including filings in jurisdictions like the US, Europe, and Japan, to ensure comprehensive protection.
- Examination of priority and related applications could reveal if this patent shares priority with prior filings or if it reflects an independent China-specific inventive step.
Patent Strategies of Competitors:
- Companies operating in similar technological areas may file overlapping or blocking patents.
- Freedom-to-operate analyses should verify if CN1747965 restricts or overlaps with other active patents, especially in compounds with similar structural motifs.
Legal and Enforcement Environment:
- China's evolving patent enforcement landscape enhances the ability to defend such patents.
- Notably, patent litigations have increased in the domestic Chinese courts, with recent high-profile decisions affirming patent rights in the pharmaceutical sector.
Innovation and Value Assessment
Strengths of CN1747965:
- Protective scope over specific chemical compounds with therapeutic potential.
- Potential for extension through patent family growth, formulation patents, and method claims.
- Alignment with China's national priorities for drug innovation, particularly in pharmaceuticals targeting unmet medical needs.
Weaknesses and Challenges:
- Potential vulnerability to prior art challenges if the inventive step is deemed insufficient.
- Narrow claims could limit enforceability or allow minor modifications to circumvent rights.
Commercial Implications:
- If valid and enforceable, CN1747965 can block competitors from marketing identical or similar compounds within China.
- Likely to underpin proprietary formulations or methods for a specific drug candidate, providing a competitive edge.
Conclusion
Patent CN1747965 exemplifies a strategic Chinese pharmaceutical patent with focused claims on a novel chemical entity or composition. Its scope appears comprehensive over specific compounds and processes, potentially supporting a significant market position in China. However, careful legal monitoring and potential family filings are advisable to maximize protection and leverage this patent within broader global strategies.
Key Takeaways
- Scope & Claims: Focused on a specific chemical compound or formulation; the breadth hinges on structural and procedural details.
- Patent Landscape: Situated within China’s active chemical patent arena, with strategic importance for drug development and market exclusivity.
- Enforceability: As a granted and unchallenged patent, CN1747965 offers a solid foundation for patent enforcement, with room for broadening through family filings.
- Competitive Strategy: Actively monitor overlapping patents; utilize this patent in conjunction with other IP rights to safeguard market position.
- Maintenance & Lifecycle: Ensure ongoing fee payments to maintain patent validity until expiration in 2025 and plan for potential extensions or supplementary protection strategies.
FAQs
1. What is the primary inventive aspect of CN1747965?
It pertains to a novel chemical compound or pharmaceutical formulation with potential therapeutic applications, protected through specific structural claims.
2. How broad are the claims in CN1747965?
The claims likely cover the core compound, its synthesis, and therapeutic methods, with dependent claims detailing specific derivatives or embodiments. The scope relies heavily on structural specificity.
3. Can CN1747965 be challenged or invalidated?
Yes, through patent invalidation proceedings if prior art disclosures or lack of inventive step are proven. However, currently, it remains valid.
4. How does CN1747965 fit into the Chinese drug patent landscape?
It aligns with China’s focus on protecting innovative chemical inventions, contributing to a competitive pharmaceutical IP environment.
5. What strategic steps should patent holders consider to maximize protection?
Filing additional filings in other jurisdictions, developing patent families, and continuously monitoring for potential infringements or overlaps.
References
- China National Patent Database. (2005). Patent CN1747965.
- State Intellectual Property Office of China. Patent publication and legal status records.
- World Intellectual Property Organization. Patent landscape reports—China pharmaceuticals.
- Chinese patent law and guidelines on pharmaceutical inventions.
- Industry reports on Chinese drug patent trends (e.g., China Patent News, 2022).
